Resmetirom was approved in 2024 for the treatment of metabolic dysfunction–associated steatotic liver disease (MASLD). Do you know its mechanism of action?
The post Which Endocrine Pathway Does Resmetirom Target? first appeared on Physician’s Weekly.
